Skip to main content

Axela Biosensors, Abnova to Co-Develop Reagents for Axela's DotLab Systems

NEW YORK (GenomeWeb News) – Axela Biosensors and Abnova of Taiwan today said they plan to co-develop reagents and biomarker panels to be used on Axela's dotLab system.
 
According to the companies, the dotLab system is a real-time protein-detection technology that can accelerate the analysis, validation, and commercialization of protein biomarkers.
 
Specifically, Abnova said it will optimize a series of monoclonal antibodies for the quantitation of specific serum protein biomarkers for use with Axela’s dotLab sensors.
 
Researchers will then be able to combine these monoclonal antibodies with their own reagents to create custom panels for multiplexed biomarker detection.
 
Financial terms of the deal were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.